What is ufh heparin

Overview

UFH (Unfractionated Heparin) is a pharmaceutical anticoagulant used to prevent and treat blood clots. It is derived from animal tissues and has been used in medicine for decades. UFH works by interrupting the blood coagulation cascade, making it an essential medication in hospital and clinical settings.

How It Works

UFH prevents clot formation by inhibiting several factors involved in blood coagulation. It enhances the activity of antithrombin III, a natural anticoagulant in the body, which then inactivates thrombin and other clotting factors. This mechanism prevents the formation of fibrin, the protein responsible for clot structure.

Administration

UFH is administered through:

• Intravenous (IV) infusion - Most common in hospital acute care settings
• Subcutaneous injection - Used for lower doses and outpatient therapy
• IV bolus - Initial loading dose followed by continuous infusion

Clinical Uses

UFH is prescribed for multiple conditions requiring anticoagulation. These include acute myocardial infarction, pulmonary embolism, deep vein thrombosis, and atrial fibrillation. It is also used during surgical procedures to prevent clot formation and is essential in dialysis and heart-lung bypass procedures.

Monitoring and Safety

UFH requires careful medical monitoring through blood tests measuring aPTT (activated partial thromboplastin time). Healthcare providers adjust dosing based on test results to maintain therapeutic anticoagulation while minimizing bleeding risk. Bleeding is the primary adverse effect, making proper dose management critical. Patients receiving UFH must be monitored for signs of excessive bleeding and heparin-induced thrombocytopenia (HIT), a serious but rare complication.

Comparison to Low Molecular Weight Heparin

UFH differs from low molecular weight heparin (LMWH) in several ways. UFH has a shorter half-life, more variable pharmacokinetics, and requires closer monitoring. However, it can be rapidly reversed with protamine and is preferred in patients with severe renal impairment or those requiring rapid anticoagulation reversal.